We are live on ! Find out more
ZSAN

Zosano Pharma Corporation
ZSAN

Delisted

ZSAN was delisted on the 10th of June, 2022.

Back to rankings

15 hedge funds and large institutions have $5.56M invested in Zosano Pharma Corporation in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more funds holding

Funds holding: 14 → 15 (+1)

4% more capital invested

Capital invested by funds: $5.33M → $5.56M (+$226K)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$378K
2
AC
Armistice Capital
New York
+$255K
3
GA
Geneva Advisors
Illinois
+$78.4K
4
VKH
Virtu KCG Holdings
New York
+$32K
5
Renaissance Technologies
Renaissance Technologies
New York
+$21.2K

Top Sellers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
-$434K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$186K
3
CC
Callan Capital
California
-$13K
4
LOAMU
Lombard Odier Asset Management (USA)
New York
-$8.38K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$1.6M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.39M – – –
AC
3
Armistice Capital
New York
$936K +$255K +517 +43%
LOAMU
4
Lombard Odier Asset Management (USA)
New York
$612K -$8.38K -17 -1%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$418K +$378K +766 New
EAM
6
Eventide Asset Management
Massachusetts
$212K -$434K -880 -69%
GA
7
Geneva Advisors
Illinois
$87K +$78.4K +159 New
SM
8
Sabby Management
Florida
$81K – – –
VC
9
Vivo Capital
California
$77K – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$52K – – –
VKH
11
Virtu KCG Holdings
New York
$35K +$32K +65 New
Renaissance Technologies
12
Renaissance Technologies
New York
$23K +$21.2K +43 New
PAM
13
Panagora Asset Management
Massachusetts
$20K – – –
Deutsche Bank
14
Deutsche Bank
Germany
$19K +$16.3K +33 +1,100%
BFA
15
BlackRock Fund Advisors
California
$2K – – –
Hudson Bay Capital Management
16
Hudson Bay Capital Management
Connecticut
– -$186K -349 Closed
CC
17
Callan Capital
California
– -$13K -24 Closed
TRCT
18
Tower Research Capital (TRC)
New York
– -$1K -1 Closed

ZSAN Hedge Fund Activity: Q4 2016 in Review

15 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Zosano Pharma Corporation (ZSAN) for Q4 2016, worth a combined $5.56M — up 4.2% from $5.33M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ZSAN positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $378K. The largest seller was Eventide Asset Management, cutting an estimated $434K.

  • 15 institutional investors held Zosano Pharma Corporation (ZSAN) as of Q4 2016, up from 14 in Q3 2016.
  • Funds reported $5.56M of Zosano Pharma Corporation stock for Q4 2016, up 4.2% quarter-over-quarter.
  • 4 funds opened new Zosano Pharma Corporation positions in Q4 2016 and 3 closed out, a net change of +1 holder.
  • The largest Zosano Pharma Corporation buyer in Q4 2016 was Susquehanna International Group, an estimated $378K added.
  • The largest Zosano Pharma Corporation seller in Q4 2016 was Eventide Asset Management, an estimated $434K sold.

Based on aggregated 13F filings for Q4 2016.